🟢 20/20 Biolabs is trading 13.66% up — no confirmed catalyst identified

20/20 Biolabs is trading 13.66% up at $0.47, with no confirmed company-specific catalyst or direct explanation identified for the September 30 move.

• On September 29, the company scheduled an October 7 investor webinar on the FDA advisory committee’s MCED deliberations and the OneTest franchise model; no connection to the rise was established.
• Broader indexes are positive, but the supplied market context shows no same-direction index move above 0.5%, so a market-driven explanation is unconfirmed.